SCOPUS 정보 검색 플랫폼

Cancer Chemotherapy and Pharmacology

Volumn 47, Issue 1, 2001, Pages 89-93

Effect of hemodialysis on topotecan disposition in a patient with severe renal dysfunction

(5) Herrington, J D a Figueroa, J A a Kirstein, M N a Zamboni, W C a Stewart, C F a

a ST JUDE CHILDREN S RESEARCH HOSPITAL (United States)

Author keywords

Hemodialysis; Kidney failure; Pharmacokinetics; Topoisomerase I inhibitors

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; LACTONE; PACLITAXEL; TOPOTECAN;

ADULT; ARTICLE; CASE REPORT; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; FEMALE; HALF LIFE TIME; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; KIDNEY FUNCTION; NEUTROPENIA; OVARY CARCINOMA; PLASMA CLEARANCE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; KIDNEY FAILURE; MIDDLE AGED; OVARIAN NEOPLASMS; RENAL DIALYSIS; TOPOTECAN;

EID: 0034923023 PISSN: 03445704 EISSN: None Source Type: Journal
DOI: 10.1007/s002800000224 Document Type: Article

Times cited : (11)

References (22)

1
- 0030223030
- Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor
- (1996) Clin Cancer Res , vol.2 , pp. 1489
- Abbruzzese, J.L.¹ Madden, T.² Sugarman, S.M.³ Ellis, A.L.⁴ Loughlin, S.⁵ Hess, K.R.⁶ Newman, R.A.⁷ Zwelling, L.A.⁸ Raber, M.N.⁹

2
- 0029656180
- Cerebrospinal fluid pharmacokinetics and penetration of continuous infusion topotecan in children with central nervous system tumors
- (1996) Cancer Chemother Pharmacol , vol.37 , pp. 195
- Baker, S.D.¹ Heideman, R.L.² Crom, W.R.³ Kuttesch, J.F.⁴ Gajjar, A.⁵ Stewart, C.F.⁶

3
- 0025597927
- High-performance liquid chromatographic analysis of the new antitumour drug SK&F 104864-A (NSC 609699) in plasma
- (1990) J Pharm Biomed Anal , vol.8 , pp. 789
- Beijnen, J.H.¹ Smith, B.R.² Keijer, W.J.³ Van Gijn, R.⁴ Huinink, W.W.⁵ Vlasveld, L.T.⁶ Rodenhuis, S.⁷ Underberg, W.J.M.⁸

4
- 0004062826
- Biomedical Simulations Resource, USC, Los Angeles
- (1990) ADAPT II User's guide, 1st edn.
- D'Argenio, D.Z.¹ Schumitzky, A.²

5
- 0004061014
- Marcel Dekker, New York
- (1982) Pharmacokinetics, 2nd edn.
- Gibaldi, M.¹ Perrier, D.²

6
- 0026646768
- Pharmacokinetics and pharmacodynamics of topotecan in patients with advanced cancer
- (1992) Drug Metab Dispos , vol.20 , pp. 706
- Grochow, L.B.¹ Rowinsky, E.K.² Johnson, R.³ Ludeman, S.⁴ Kaufmann, S.H.⁵ McCabe, F.L.⁶ Hurowitz, L.⁷ DeLisa, A.⁸ Donehower, R.C.⁹

7
- 0029947777
- Clinical pharmacokinetics of topotecan
- (1996) Clin Pharmacokinet , vol.31 , pp. 85
- Herben, V.M.¹ Ten Bokkel Huinink, W.W.² Beijnen, J.H.³

8
- 0029966916
- Phase I and pharmacologic study of topotecan in patients with impaired renal function
- (1996) J Clin Oncol , vol.14 , pp. 3062
- O'Reilly, S.¹ Rowinsky, E.K.² Slichenmeyer, W.³ Donehower, R.C.⁴ Forastiere, A.A.⁵ Ettinger, D.S.⁶ Chen, T.L.⁷ Sartorius, S.⁸ Grochow, L.B.⁹

9
- 0031456165
- Life-threatening myelosuppression in patients with occult renal impairment receiving topotecan
- (1997) Gynecol Oncol , vol.67 , pp. 329
- O'Reilly, S.¹ Armstrong, D.K.² Grochow, L.B.³

10
- 0028267240
- Camptothecins: From bench research to hospital wards
- (1994) Cancer Res , vol.54 , pp. 1431
- Potmesil, M.¹

11
- 0028357993
- Phase I study of topotecan for pediatric patients with malignant solid tumors
- (1994) J Clin Oncol , vol.12 , pp. 539
- Pratt, C.B.¹ Stewart, C.F.² Santana, V.M.³ Bowman, L.⁴ Furman, W.⁵ Ochs, J.⁶ Marina, N.⁷ Kuttesch, J.F.⁸ Heideman, R.⁹ Sandlund, J.T.¹⁰ Avery, L.¹¹ Meyer, W.H.¹²

12
- 0032489634
- Crystal structures of human topoisomerase I in covalent and noncovalent complexes with DNA
- (1998) Science , vol.279 , pp. 1504
- Redinbo, M.R.¹ Stewart, L.² Kuhn, P.³ Champoux, J.J.⁴ Hol, W.G.J.⁵

13
- 0026537874
- Phase I and pharmacologic study of topotecan: A novel topoisomerase I inhibitor
- (1992) J Clin Oncol , vol.10 , pp. 647
- Rowinsky, E.K.¹ Grochow, L.B.² Hendricks, C.B.³ Ettinger, D.S.⁴ Forastiere, A.A.⁵ Hurowitz, L.A.⁶ McGuire, W.P.⁷ Sartorius, S.E.⁸ Lubejko, B.G.⁹ Kaufmann, S.H.¹⁰

14
- 0027323646
- Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor
- published erratum appears in J Natl Cancer Inst 1993 85(21):1777
- (1993) J Natl Cancer Inst , vol.85 , pp. 1499
- Saltz, L.¹ Sirott, M.² Young, C.³ Tong, W.⁴ Niedzwiecki, D.⁵ Tzy-Jyun, Y.⁶ Tao, Y.⁷ Trochanowski, B.⁸ Wright, P.⁹ Barbosa, K.¹⁰

15
- 0026623528
- Mathematic modeling of drug disposition and postdialysis rebound in patients requiring hemodialysis
- (1992) Pharmacotherapy , vol.12 , pp. 201
- Spivey, J.M.¹ Blum, R.A.² Nix, D.E.³

16
- 0028130504
- Clinical pharmacodynamics of continuous infusion topotecan in children: Systemic exposure predicts hematologic toxicity
- (1994) J Clin Oncol , vol.12 , pp. 1946
- Stewart, C.F.¹ Baker, S.D.² Heideman, R.L.³ Jones, D.⁴ Crom, W.R.⁵ Pratt, C.B.⁶

17
- 10244270659
- Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Groap Study
- (1996) J Pediatr Hematol Oncol , vol.18 , pp. 352
- Tubergen, D.G.¹ Stewart, C.F.² Pratt, C.B.³ Zamboni, W.C.⁴ Winick, N.⁵ Santana, V.M.⁶ Dryer, Z.A.⁷ Kurtzberg, J.⁸ Bell, B.⁹ Grier, H.¹⁰ Vietti, T.J.¹¹

18
- 0028796513
- Pharmacokinetics and pharmacodynamics of topotecan administered daily for 5 days every 3 weeks
- (1995) Cancer Chemother Pharmacol , vol.35 , pp. 237
- Van Warmerdam, L.J.¹ Verweij, J.² Schellens, J.H.³ Rosing, H.⁴ Davies, B.E.⁵ De Boer-Dennert, M.⁶ Maes, R.A.⁷ Beijnen, J.H.⁸

19
- 0026697849
- A phase I clinical and pharmacokinetic study of topoisomerase I inhibitor topotecan (SK&F 104864) given as an intravenous bolus every 21 days
- (1992) Anticancer Drugs , vol.3 , pp. 337
- Wall, J.G.¹ Burris, H.A.² Von Hoff, D.D.³ Rodriguez, G.⁴ Kneuper-Hall, R.⁵ Shaffer, D.⁶ O'Rourke, T.⁷ Brown, T.⁸ Weiss, G.⁹ Clark, G.¹⁰ McVea, S.¹¹ Brown, J.¹² Johnson, R.¹³ Friedman, C.¹⁴ Smith, B.¹⁵ Mann, W.S.¹⁶ Kuhn, J.¹⁷

20
- 0000149103
- Pharmacokinetics (PK) of topotecan in pediatric patients with normal and altered renal function
- (1996) Proc Am Soc Clin Oncol , vol.15 , pp. 371
- Zamboni, W.C.¹ Heideman, R.L.² Meyer, W.H.³ Gajjar, A.J.⁴ Crom, W.R.⁵ Stewart, C.F.⁶

21
- 15444358162
- Probenecid alters topotecan systemic and renal disposition by inhibiting tubular secretion
- (1998) J Pharmacol Exp Ther , vol.284 , pp. 89
- Zamboni, W.C.¹ Houghton, P.J.² Johnson, R.K.³ Hulstein, J.L.⁴ Crom, W.R.⁵ Cheshire, P.J.⁶ Hanna, S.K.⁷ Richmond, L.B.⁸ Stewart, C.F.⁹

22
- 0032054147
- Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
- (1998) J Natl Cancer Inst , vol.90 , pp. 505
- Zamboni, W.C.¹ Stewart, C.F.² Thompson, J.³ Santana, V.M.⁴ Cheshire, P.J.⁵ Richmond, L.B.⁶ Luo, X.⁷ Poquette, C.⁸ Houghton, J.A.⁹ Houghton, P.J.¹⁰

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.